Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients

Inclusion Criteria: 1. Histological verified malignant melanoma 2. Metastatic disease (brain metastasis allowed if asymptomatic) 3. Evaluable disease recording to RECIST v. 1.1 4. Age \> 18 years 5. Performance status, PS=0, PS=1 or PS=2 6. Life expectancy \> 3 months 7. Adequate bone marrow function 8. Leucocyte count \> 2,5 \* 109/L 9. Granulocyte count \> 1,5 \* 109/L 10. Thrombocyte count \> 100 \* 109/l 11. Creatinine \< 2,5 \* UNL 130 micromol/L 12. Adequate liver function 13. ASAT \< 100 U/L 14. Bilirubin \< 300 U/L 15. S-hCG negative (fertile women) 16. Written informed consent 17. Inclusion at least 4 weeks after major abdominal surgery 18. If radiotherapy for brain metastases prior to inclusion, then progressive disease proven by new brain MR-scan before inclusion Exclusion Criteria: 1. Treatment with immune suppressors (ie. prednisone) not allowed 2. Other malignancies 3 years prior to inclusion except benign skin lesions 3. Severe medical condition, severe asthma, severe COL, severe heart- or diabetic disease 4. Acute/Chronic infection with HIV, hepatitis or tuberculosis 5. Known severe allergic reactions 6. Former anaphylactic reactions 7. Active autoimmune diseases 8. Pregnant or nourishing women 9. Psychiatric disease resulting in non-compliance 10. Known allergic reactions towards Montanide, Imiquimod, Temozolomide or Leukine 11. Simultaneously treatment with other experimental drugs Patients cannot be treated with chemotherapy, radiotherapy (except locally) or immunotherapy 14 days within inclusion.